Publication at Second Faculty of Medicine |
2015
Abstract
In a recent paper, McClellan et al. report that blasts from some precursor B cell acute lymphoblastic leukemia (B-ALL) cases transdifferentiate (reprogram) into nonmalignant cells. Although showing induced reprogramming in both Philadelphia chromosome-positive (Ph+) and PhMINUS SIGN cases, the authors concentrate on Ph+ leukemias, proposing reprogramming to be a possible therapeutic modality for this high-risk group of B-ALLs.
Although the findings are highly interesting and relevant, we would like to raise several points of concern.